Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to PARP inhibitors. To understand resistance mechanisms, we conducted whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in BRCA1-deficient breast cancer cells treated with PARP inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Dev, Harveer, Will Chiang, Ting-Wei, Lescale, Chloe, de Krijger, Inge, Martin, Alistair G., Pilger, Domenic, Coates, Julia, Sczaniecka-Clift, Matylda, Wei, Wenming, Ostermaier, Matthias, Herzog, Mareike, Lam, Jonathan, Shea, Abigail, Demir, Mukerrem, Wu, Qian, Yang, Fengtang, Fu, Beiyuan, Lai, Zhongwu, Balmus, Gabriel, Belotserkovskaya, Rimma, Serra, Violeta, O’Connor, Mark J., Bruna, Alejandra, Beli, Petra, Pellegrini, Luca, Caldas, Carlos, Deriano, Ludovic, Jacobs, Jacqueline J.L., Galanty, Yaron, Jackson, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145444/
https://www.ncbi.nlm.nih.gov/pubmed/30022119
http://dx.doi.org/10.1038/s41556-018-0140-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145444/
https://www.ncbi.nlm.nih.gov/pubmed/30022119
http://dx.doi.org/10.1038/s41556-018-0140-1

Ejemplares similares